| 应用 |
A dual PI3K and mTOR inhibitor |
| 产品介绍 |
BEZ235 (NVP-BEZ235, Dactolisib) ATP竞争性的抑制PI3K和mTOR，对p110α/γ/δ/β和mTOR(p70S6K)均有抑制作用，IC50分别为4 nM/5 nM/7 nM/75 nM/6 nM，对ATR也有抑制作用，IC50为21 nM；但对Akt和PDK1抑制作用微弱。 |
| 备注 |
BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively. Inhibits ATR with IC50 of 21 nM; shown to be poor inhibitory to |
| 生化机理 |
BEZ235 is a PI 3-kinase (PI3K) tyrosine kinase inhibitor and shows dual PI3K/mTOR inhibition (IC50 = 4, 5, 7 and 75 nM for PI 3-Kα, -γ, -δ, and -β, respectively). BEZ235 showed high target specificity and demonstrated antiproliferative activity against tumor cell lines in animal models of cancer. BEZ235 is an mTOR Complex 1 and mTOR Complex 2 catalytic inhibitor. BEZ235 also inhibits ATR (IC50 = 21nM). |
| 别名 |
2-甲基-2-[4-[3-甲基-2-氧代-8-(喹啉-3-基)-2,3-二氢咪唑并[4,5-C]喹啉-1-基]苯基]丙腈;NVP-BEZ235, Dactolisib;PI3K抑制剂;2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile |
2850412321
